FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:817-818 September 9, 1993 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

By Howard P. Greenwald. 280 pp. Berkeley, Calif., University of California Press, 1992. $25. ISBN 0-520-07725-3.

Who, indeed, survives cancer? We know a great deal at a rough descriptive level. The clinical stage at the time of diagnosis matters a lot; the anatomical stage matters more. The histologic type matters, and so do many microscopical features of cells and tissues. The laboratory can tell us something (e.g., estrogen-receptor status). The type, timing, and quality of treatment can be important.

Overall, very close to 50 percent of patients with cancer in the United States are alive five years after diagnosis (with adjustment for mortality due to unrelated causes), but a wise and well-informed physician could divide the . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.